Self-Administered Relaxing Acupressure to Reduce Fatigue in Adolescent and Young Adult Cancer Survivors
Launched by UNIVERSITY OF MICHIGAN ROGEL CANCER CENTER · May 30, 2024
Trial Information
Current as of February 08, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring whether self-administered relaxing acupressure can help reduce fatigue in adolescent and young adult cancer survivors. Acupressure involves applying gentle pressure to specific points on the body, similar to massage, and has been shown to help alleviate fatigue in adult cancer patients. The researchers want to see if this method can also benefit younger survivors who are experiencing fatigue after their cancer treatments.
To be eligible for the study, participants must be between 15 and 39 years old, at least three months past their cancer treatment, and currently experiencing significant fatigue. They should also be able to read and speak English and have completed their cancer treatment within the last five years. Unfortunately, individuals with certain medical conditions or those who have recently received acupressure or acupuncture are not eligible. If you choose to participate, you will learn how to perform acupressure on yourself, and the study aims to see how effective this technique is in helping you feel less tired.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 15 - 39 years old
- • At least three months post cancer treatment (e.g., surgery, radiation or chemotherapy). Participants receiving maintenance hormonal or targeted therapies will be allowed to enroll as determined by the study investigator
- • Report clinically relevant fatigue in the past seven days (Patient Reported Outcomes Measurement Information Systems \[PROMIS\] Fatigue 4a scores ≥ 55)
- • Speak / read English
- • CRF started at or after the diagnosis of cancer
- • Completed cancer treatment within the past five years
- Exclusion Criteria:
- • Diagnosis of untreated anemia, mood disorder, or hypothyroidism
- • Plan to begin new pharmacological, psychological, or other treatments (i.e., physical therapy or dietary supplements) for CRF during the study. Although, participants may continue usual treatments for CRF if the treatments were initiated at least eight weeks prior to study enrollment, and the dose has not changed
- • Plan to become pregnant or lactating during the study period
- • Received acupressure or acupuncture in the past year
Trial Officials
Robert Knoerl
Principal Investigator
University of Michigan Rogel Cancer Center
About University Of Michigan Rogel Cancer Center
The University of Michigan Rogel Cancer Center is a leading academic research institution dedicated to advancing cancer treatment and prevention through innovative clinical trials. As a National Cancer Institute-designated Comprehensive Cancer Center, it combines cutting-edge research, state-of-the-art facilities, and a multidisciplinary team of experts to deliver personalized care and foster groundbreaking discoveries. The center's commitment to improving patient outcomes is reflected in its robust portfolio of clinical trials, which explore novel therapies and enhance understanding of cancer biology. Through collaboration with patients, researchers, and healthcare professionals, the Rogel Cancer Center aims to translate scientific insights into transformative therapies, ultimately contributing to the global fight against cancer.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ann Arbor, Michigan, United States
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0